LIN vs PPCB · P/E 34, rev $33.99B vs P/E 0.0, $3.9M cap
Linde plc Ordinary Shares (LIN) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
PPCB does not have a complete income-statement cache yet.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the LIN and PPCB stock pages for the full models.
Not investment advice.